Department of Forensic Medicine, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education, Xi'an Jiaotong University School of Medicine, Yanta Road West 76#, Xi'an, Shaanxi 710061, PR China.
Neuroscience. 2010 Sep 15;169(4):1872-80. doi: 10.1016/j.neuroscience.2010.06.050. Epub 2010 Jun 30.
The present study examined the role of dopamine and D(1)-and D(2)-like dopamine receptors in ventrolateral orbital cortex (VLO)-evoked anti-hypersensitivity in a rat model of neuropathic pain, as well as the possible underlying mechanisms. Results showed that microinjection of apomorphine [(R(-)-apomorphine hydrochloride)], a non-selective dopamine receptor agonist, into the VLO attenuated spared nerve injury (SNI)-induced mechanical allodynia in a dose-dependent manner. This effect was completely blocked by the D(2)-like dopamine receptor antagonist S(-)-raclopride(+)-tartrate salt (1.5 microg), but was enhanced by the D(1)-like dopamine receptor antagonist SCH23390 (R(+)-SCH-23390 hydrochloride, 5.0 microg). The attenuating effect of apomorphine on mechanical allodynia was mimicked by application of the D(2)-like dopamine receptor agonist quinpirole [((-)-quinpirole hydrochloride, 0.5, 1.0, and 2.0 microg)]. In addition, microinjection of larger doses (10 and 20 microg) of SCH23390 into the VLO significantly attenuated allodynia. Furthermore, microinjections of GABA(A) receptor antagonists, bicuculline [(+)-bicuculline,(S), 9(R)] and picrotoxin (200 and 300 ng for both drugs), into the VLO attenuated mechanical allodynia. A small dose of bicuculline or picrotoxin (100 ng) resulted in increased quinpirole (0.5 microg)-induced anti-allodynia. In contrast, GABA(A) receptor agonists, muscimol hydrochloride (250 ng) or THIP [(2,5,6,7-retrahydroisoxazolo(5,4-c)pyridine-3-ol hydrochloride, 1.0 microg)], blocked quinpirole (2.0 microg)-induced attenuation. These results suggest that the dopaminergic system is involved in mediating VLO-induced anti-hypersensitivity, activation of D(2)-like dopamine receptors, and inhibition of D(1)-like receptors resulting in anti-hypersensitivity. In addition, the mechanisms of GABAergic disinhibition might be involved in D(2)-like receptor mediating effects in neuropathic pain.
本研究探讨了多巴胺和 D(1)-和 D(2)-样多巴胺受体在外侧眶皮层(VLO)诱发神经病理性疼痛模型中的抗敏作用中的作用,以及潜在的机制。结果表明,将非选择性多巴胺受体激动剂阿朴吗啡[(R(-)-阿朴吗啡盐酸盐)]微注射到 VLO 中以剂量依赖性方式减弱了 spared 神经损伤(SNI)诱导的机械性痛觉过敏。这种作用完全被 D(2)-样多巴胺受体拮抗剂 S(-)-raclopride(+)-tartrate salt(1.5μg)阻断,但被 D(1)-样多巴胺受体拮抗剂 SCH23390(R(+)-SCH-23390盐酸盐,5.0μg)增强。阿朴吗啡对机械性痛觉过敏的减弱作用被 D(2)-样多巴胺受体激动剂喹吡罗[(−)-喹吡罗盐酸盐,0.5、1.0 和 2.0μg)模拟。此外,将较大剂量(10 和 20μg)的 SCH23390 微注射到 VLO 中可显著减弱痛觉过敏。此外,将 GABA(A)受体拮抗剂,荷包牡丹碱[(+)-荷包牡丹碱,(S),9(R)]和培高利特(两种药物均为 200 和 300ng)微注射到 VLO 中可减弱机械性痛觉过敏。荷包牡丹碱或培高利特的小剂量(100ng)导致喹吡罗(0.5μg)诱导的抗痛觉过敏增加。相比之下,GABA(A)受体激动剂,盐酸 muscimol(250ng)或 THIP[(2,5,6,7- 四氢异恶唑(5,4-c)吡啶-3-醇盐酸盐,1.0μg)]阻断了喹吡罗(2.0μg)诱导的减弱。这些结果表明,多巴胺能系统参与介导 VLO 诱导的抗敏作用,激活 D(2)-样多巴胺受体,并抑制 D(1)-样受体导致抗敏作用。此外,GABA 能抑制的机制可能参与 D(2)-样受体介导的神经病理性疼痛中的作用。